{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "cholangiocarcinoma",
      "hepatobilarry cancer",
      "hepatocellular carcinoma",
      "liver cancer",
      "signaling pathway"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "35546130",
  "DateCompleted": {
    "Year": "2022",
    "Month": "05",
    "Day": "17"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "07",
    "Day": "16"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "15330338221097203",
      "10.1177/15330338221097203"
    ],
    "Journal": {
      "ISSN": "1533-0338",
      "JournalIssue": {
        "Volume": "21",
        "PubDate": {
          "Year": "2022",
          "Season": "Jan-Dec"
        }
      },
      "Title": "Technology in cancer research & treatment",
      "ISOAbbreviation": "Technol Cancer Res Treat"
    },
    "ArticleTitle": "Hepatobiliary Cancers: Progress in Diagnosis, Pathogenesis, and Treatment.",
    "Pagination": {
      "StartPage": "15330338221097203",
      "MedlinePgn": "15330338221097203"
    },
    "Abstract": {
      "AbstractText": [
        "Hepatobiliary cancers comprise a wide range of malignancies such as hepatocellular carcinoma and cholangiocarcinoma, and they are some of the most challenging to treat human neoplasms. Due to the rarity of the illnesses, the development of treatment measures for malignancies of the gastrointestinal system is far behind. The number of patients eligible for curative treatment is limited due to cancer's aggressive nature and the difficulties of early identification. Furthermore, surgery is frequently intrusive and linked with a significant level of risk. The therapy result of hepatobiliary cancers is unsatisfactory due to these complicated variables, leaving significant space for improvement."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0002-3505-6616"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "The Hormel Institute, 5635University of Minnesota, Austin, MN, USA."
          }
        ],
        "LastName": "Pant",
        "ForeName": "Kishor",
        "Initials": "K"
      },
      {
        "Identifier": [
          "0000-0002-1753-3634"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "The Hormel Institute, 5635University of Minnesota, Austin, MN, USA."
          },
          {
            "Identifier": [],
            "Affiliation": "Masonic Cancer Center, 5635University of Minnesota, Minneapolis, MN, USA."
          }
        ],
        "LastName": "Gradilone",
        "ForeName": "Sergio A",
        "Initials": "SA"
      }
    ],
    "PublicationTypeList": [
      "Editorial"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Technol Cancer Res Treat",
    "NlmUniqueID": "101140941",
    "ISSNLinking": "1533-0338"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Bile Duct Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Bile Ducts, Intrahepatic"
    },
    {
      "QualifierName": [
        "diagnosis",
        "etiology",
        "therapy"
      ],
      "DescriptorName": "Carcinoma, Hepatocellular"
    },
    {
      "QualifierName": [
        "diagnosis",
        "etiology",
        "therapy"
      ],
      "DescriptorName": "Cholangiocarcinoma"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "diagnosis",
        "etiology",
        "therapy"
      ],
      "DescriptorName": "Liver Neoplasms"
    }
  ],
  "CoiStatement": "<b>Declaration of Conflicting Interests:</b> The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article."
}